Darifenacin

Darifenacin has been studied in 4 papers since 2021: 4 observational studies in people; 1 in the past year. The newest story, Nov 6, 2026: “Bladder drugs presumed safer not linked to lower dementia risk”.

Intervention

4 papers study it3 more mention it2 findingsUpdated Nov 6, 2026

PubChem ChEBI

1 new paper in 30 daysSee all 7 papers on darifenacin

At a glance

The findings reach people, from one lab or study. 2 independent labs in 2 countries; 1 trial, 1 about aging, 1 with no results posted.

“No significant increases in the risk of dementia associated with darifenacin, fesoterodine fumarate, flavoxate hydrochloride, propiverine hydrochloride, and trospium chloride were found.”

Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control studyBMJ medicine2024doi:10.1136/bmjmed-2023-000799

1 of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

About aging: the drug’s trials about aging. The total counts its trials for every use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries
1 finding against
1 trial, 1 about aging, 1 with no results posted

Funders: Department of Health and Social Care and 6 more
1 of 2 findings with company ties
1 of 1 trial sponsored by its developers

Humans4

What did studies of darifenacin find?

Studies of darifenacin measured 1 outcome; the most studied are dementia (1 study).

Dementia

no changein humans1

1 study

Darifenacin was not clearly linked with dementia in humans.
“No significant increases in the risk of dementia associated with darifenacin, fesoterodine fumarate, flavoxate hydrochloride, propiverine hydrochloride, and trospium chloride were found.”
Humans
Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study
BMJ medicineNov 12, 2024

What is darifenacin linked with?

Studies link darifenacin with 1 measure, most often dementia (1 study).

Dementia

upin humans1OR 1.3

1 study

Darifenacin is linked with a higher risk of dementia in humans (compared with mirabegron) (OR 1.30; 95% CI 1.08-1.56).
“Patients receiving solifenacin (OR 1.24; 95% confidence interval 1.08-1.43) and darifenacin (OR 1.30; 95% CI 1.08-1.56) in the prior 6 mo had increased odds of incident dementia compared with those receiving mirabegron.”
Humanscompared with mirabegronprior 6 mo
Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study
European urology focusNov 4, 2021

Has darifenacin been tested in people?

1 of 1 about aging

Yes: 4 observational studies in people have been published.

About aging

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
Phase 2Completed

Trial sponsors

Novartis
Company1 trialPhase 2150 people

Latest

1 paper in 12 months

JAMA Network OpenNov 6

Bladder drugs presumed safer not linked to lower dementia risk

Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.

Cohort · 830,393 peopleIncident dementia